{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:44:02Z","timestamp":1780595042169,"version":"3.54.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Foodborne Pathogens and Disease"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>\n                    The study objective was to determine effects of fluoroquinolone metaphylaxis on fecal prevalence of\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    and fecal prevalence of quinolone-resistant\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    in feedlot cattle. On Day 0, cattle (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u2009288) at risk for bovine respiratory disease (BRD) were randomly assigned to either a nontreated control pen (12 pens) or a fluoroquinolone-treated (enrofloxacin; Baytril\n                    <jats:sup>\u00ae<\/jats:sup>\n                    100) pen (12 pens). Rectal fecal samples were collected from cattle on days 0, 7, 14, 21, and 28. Feces were cultured for\n                    <jats:italic toggle=\"yes\">Salmonella enterica<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    spp. using enrichment and selective isolation methods, and confirmed by serology and PCR. Susceptibilities to nalidixic acid and ciprofloxacin were determined using microbroth dilution methods. Data analyses were performed using linear mixed models. Overall,\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    sp. and\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    spp. were recovered from 10.2% (139\/1,364) and 12.4% (170\/1,364) of the fecal samples, respectively.\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    species included\n                    <jats:italic toggle=\"yes\">hyointestinalis<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">jejuni<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">coli<\/jats:italic>\n                    . Neither\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    sp. nor\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    spp. prevalence was significantly impacted by fluoroquinolone treatment (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.80,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.61, respectively). However,\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    prevalence differed between study weeks (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u20090.01) with prevalence decreasing over time. Before treatment, 98.9% (91\/92) of\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    isolates were susceptible to nalidixic acid and ciprofloxacin. All\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    recovered posttreatment (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u200943) were susceptible to both antimicrobials. The majority of\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    spp. recovered before treatment were resistant to nalidixic acid (23\/35; 65.7%) and ciprofloxacin (21\/35; 60.0%). There was no significant treatment by week interaction (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.85) or treatment effects (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.61) on the posttreatment prevalence of\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    resistance. There was, however, a significant week effect (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009=\u20090.05), with\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    resistance prevalence decreasing over time. In this 28-day study, we found no evidence that a fluoroquinolone used for metaphylaxis significantly impacts fecal prevalence of\n                    <jats:italic toggle=\"yes\">Salmonella<\/jats:italic>\n                    sp. or\n                    <jats:italic toggle=\"yes\">Campylobacter<\/jats:italic>\n                    spp. or the fecal prevalence of nalidixic acid or ciprofloxacin resistance.\n                  <\/jats:p>","DOI":"10.1089\/fpd.2017.2282","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T17:05:57Z","timestamp":1501693557000},"page":"600-607","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["A Randomized Trial to Assess the Effect of Fluoroquinolone Metaphylaxis on the Fecal Prevalence and Quinolone Susceptibilities of\n                    <i>Salmonella<\/i>\n                    and\n                    <i>Campylobacter<\/i>\n                    in Feedlot Cattle"],"prefix":"10.1177","volume":"14","author":[{"given":"Ashley B.","family":"Smith","sequence":"first","affiliation":[{"name":"Kansas State University"},{"name":"Bayer Animal Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Renter","sequence":"additional","affiliation":[{"name":"Kansas State University"},{"name":"Kansas State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Cernicchiaro","sequence":"additional","affiliation":[{"name":"Kansas State University"},{"name":"Kansas State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Shi","sequence":"additional","affiliation":[{"name":"Kansas State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Nickell","sequence":"additional","affiliation":[{"name":"Bayer Animal Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Keil","sequence":"additional","affiliation":[{"name":"Bayer Animal Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.G.","family":"Nagaraja","sequence":"additional","affiliation":[{"name":"Kansas State University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,10,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0501.990104"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4315\/0362-028X-65.2.280"},{"key":"e_1_3_3_4_1","first-page":"689","article-title":"An evaluation of antimicrobial therapy for undifferentiated bovine respiratory disease","volume":"31","author":"Bateman KG","year":"1990","unstructured":"Bateman KG, , Martin SW, , Shewen PE, , Menzies PI. An evaluation of antimicrobial therapy for undifferentiated bovine respiratory disease. Can Vet J, 1990; 31:689\u2013696.","journal-title":"Can Vet J"},{"key":"e_1_3_3_5_1","unstructured":"Bayer Healthcare LLC. Freedom of Information (FOI) summary: Baytril\u00ae 100. NADA 141-068. Available at: www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIAAntimicrobialsummaries\/UCM256760.pdf accessed July24 2012."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.4315\/0362-028X-65.11.1694"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2013.06.004"},{"key":"e_1_3_3_8_1","unstructured":"[CDC] Centers for Disease Control and Prevention. \u201cSalmonella and Campylobacter Illnesses on the Decline.\u201d 1999. Available at: www.cdc.gov\/media\/pressrel\/r990311.htm accessed October2016."},{"key":"e_1_3_3_9_1","unstructured":"[CDC] Centers for Disease Control and Prevention. \u201cWhat is Campylobacteriosis?\u201d 2014. Available at: www.cdc.gov\/foodsafety\/diseases\/campylobacter\/index.html accessed May2016."},{"key":"e_1_3_3_10_1","unstructured":"[CDC] Centers for Disease Control and Prevention. \u201cSalmonella.\u201d 2015. Available at: www.cdc.gov\/salmonella\/ accessed May2016."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00600-06"},{"key":"e_1_3_3_12_1","volume-title":"Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from cattle; Approved Standard-3rd ed. CLSI document M31-A3","author":"[CLSI] Clinical and Laboratory Standards Institute","year":"2008","unstructured":"[CLSI] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from cattle; Approved Standard-3rd ed. CLSI document M31-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008."},{"key":"e_1_3_3_13_1","volume-title":"Performance standards for susceptibility testing; 23rd Informational Supplement. CLSI document M100- S23","author":"[CLSI] Clinical and Laboratory Standards Institute","year":"2013","unstructured":"[CLSI] Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing; 23rd Informational Supplement. CLSI document M100- S23. Wayne, PA: Clinical and Laboratory Standards Institute, 2013."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.4315\/0362-028X-63.12.1648"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvfa.2010.03.005"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.2005.02609.x"},{"key":"e_1_3_3_17_1","volume-title":"National Antimicrobial Resistance Monitoring System (NARMS): 2011 Retail Meat Report","author":"[FDA] U.S. Food and Drug Administration","year":"2013","unstructured":"[FDA] U.S. Food and Drug Administration. National Antimicrobial Resistance Monitoring System (NARMS): 2011 Retail Meat Report. Rockville, MD: FDA, 2013."},{"key":"e_1_3_3_18_1","volume-title":"National Antimicrobial Resistance Monitoring System (NARMS): 2012 Human Isolates Final Report","author":"[FDA] U.S. Food and Drug Administration","year":"2014","unstructured":"[FDA] U.S. Food and Drug Administration. National Antimicrobial Resistance Monitoring System (NARMS): 2012 Human Isolates Final Report. Rockville, MD: FDA, 2014."},{"key":"e_1_3_3_19_1","volume-title":"National Antimicrobial Resistance Monitoring System (NARMS): 2012 Retail Meat Report","author":"[FDA] U.S. Food and Drug Administration","year":"2015","unstructured":"[FDA] U.S. Food and Drug Administration. National Antimicrobial Resistance Monitoring System (NARMS): 2012 Retail Meat Report. Rockville, MD: FDA, 2015."},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(00)00230-3"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00362-14"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2007.0068"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvfa.2015.05.008"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prevetmed.2012.02.012"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.4315\/0362-028X-70.2.476"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2013.1642"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02076-07"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.390-394.2003"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/339195"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2005.12.030"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fm.2005.06.004"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.20506\/rst.31.1.2106"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.07723-11"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044662"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-6445(03)00019-6"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025778"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00428-11"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/fpd.2015.2081"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2014.01.036"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.457"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47363-0"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2005.12.031"}],"container-title":["Foodborne Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/fpd.2017.2282","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/fpd.2017.2282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/fpd.2017.2282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:22:20Z","timestamp":1777443740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/fpd.2017.2282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1089\/fpd.2017.2282"],"URL":"https:\/\/doi.org\/10.1089\/fpd.2017.2282","relation":{},"ISSN":["1535-3141","1556-7125"],"issn-type":[{"value":"1535-3141","type":"print"},{"value":"1556-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}